Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics, IviGen, iGenomix Ink Exclusive Reproductive Genetics Pact

NEW YORK (GenomeWeb) — Good Start Genetics, IviGen, and IviGen's parent company iGenomix today announced an exclusive partnership to offer reproductive genetics products and services to in vitro fertilization specialists and women's health professionals in the US and Canada.

The partnership enables Cambride, Mass.-based Good Start to complement its carrier screening offering with a number of genetics-based reproductive health products developed by Valenica, Spain-based IviGen and iGenomix. These include products for preimplantation genetic diagnosis and screening, products of conception testing, endometrial receptivity arrays, and sperm aneuploidy testing.

The relationship represents "a transformative step in establishing Good Start as a comprehensive, reproductive health company, serving the needs of a broad range of IVF, MFM and OBGYN physicians,” Good Start President and CEO Don Hardison said in a statement. "IviGen has rigorously developed a set of high-quality, state-of-the-art technologies already in use by leading IVF centers across the US."

David Jimenez, CEO of IviGen and iGenomix, noted that the partnership feeds into its mission "to become the leading provider of genetic testing services to the reproductive health community" and represents "a great opportunity for us to work with one of the most advanced teams in the world in relation to genetic solutions based on next-generation DNA sequencing."

Earlier this week, Good Start Genetics said that it had exclusively licensed a preimplantation genetic screening test from Johns Hopkins University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.